Two-Drug cocktail targets Hard-to-Treat hodgkin lymphoma
Disease control
Recruiting now
This study tests two drugs—nivolumab and ruxolitinib—together in people whose Hodgkin lymphoma has returned or not responded to treatment. The goal is to find the safest dose of ruxolitinib when combined with a fixed dose of nivolumab, and to see if the combination can control th…
Phase: PHASE1, PHASE2 • Sponsor: Veronika Bachanova • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC